Cost-effectiveness of combination therapy versus antidepressant therapy for management of depression in Japan

Australian and New Zealand Journal of Psychiatry

Volumn 43, Issue 6, 2009, Pages 539-547

  Sado, Mitsuhiro ^a   Knapp, Martin ^b   Yamauchi, Keita ^c   Fujisawa, Daisuke ^a   So, Mirai ^d   Nakagawa, Atsuo ^a   Kikuchi, Toshiaki ^a   Ono, Yutaka ^c  

^a KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b LONDON SCHOOL OF ECONOMICS   (United Kingdom)

^c KEIO UNIVERSITY   (Japan)

^d NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

Antidepressants; Cognitive behaviour therapy; Cost effectiveness study; Depression

Indexed keywords

ANTIDEPRESSANT AGENT; IMIPRAMINE; PAROXETINE;

ARTICLE; CLINICAL TRIAL; COGNITIVE THERAPY; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DEPRESSION; DISEASE SEVERITY; DRUG COST; DRUG WITHDRAWAL; HEALTH CARE SYSTEM; HUMAN; INCREMENTAL COST EFFECTIVENESS RATIO; JAPAN; MATHEMATICAL PARAMETERS; PERCEPTION; PRODUCTIVITY; PSYCHOPHARMACOTHERAPY; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ANTIDEPRESSIVE AGENTS; COGNITIVE THERAPY; COMBINED MODALITY THERAPY; COST-BENEFIT ANALYSIS; DEPRESSIVE DISORDER, MAJOR; HUMANS; JAPAN; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 68049110520     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670902873664     Document Type: Article

References (36)

1. Brown P. Effective treatments for mental illness not being used, WHO says. BMJ 2001; 323:769.
2. Demyttenaere K, Bruffaerts R, Posada-Villa J et al. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA 2004; 291:2581-2590.
3. Kawakami N, Takeshima T, Ono Y et al. Twelve-month prevalence, severity, and treatment of common mental disorders in communities in Japan: Preliminary finding from the World Mental Health Japan Survey 2002-2003. Psychiatry Clin Neurosci 2005; 59:441-452.
4. Thomas CM, Morris S. Cost of depression among adults in England in 2000. Br J Psychiatry 2003; 183:514-519.
5. Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. The economic burden of depression in 1990. J Clin Psychiatry 1993; 54:405-418.
6. Kind P, Sorensen J. The costs of depression. Int Clin Psychopharmacol 1993; 7:191-195.
7. Ministry of Health Labour and Welfare of Japan. White paper on the Labour Economy. Tokyo: Ministry of Health Labour and Welfare of Japan, 2005.
8. Borghi J, Guest JF, Economic impact of using mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in the UK. Eur Psychiatry 2000; 15:378-387.
9. Brown MC, Nimmerrichter AA, Guest JF. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria. Eur Psychiatry 1999; 14:230-244.
10. Doyle JJ, Casciano J, Arikian S, Tarride JE, Gonzalez MA, Casciano R. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): A comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs. Value Health 2001; 4:16-31.
11. Forder J, Kavanagh S, Fenyo A. A comparison of the costeffectiveness of sertraline versus tricyclic antidepressants in primary care. J Affect Disord 1996; 38:97-111.
12. National Collaborating Centre for Mental Health Commissioned by NICE. Management of depression in primaryand secondary care, National Clinical Practice Guideline Number 23. London: National Collaborating Centre for Mental Health, 2004.
13. Blackburn IM, Moore RG. Controlled acute and follow-up trial of cognitive therapy and pharmacotherapy in outpatients with recurrent depression. Br J Psychiatry 1997; 171:328-334.
14. Scott C, Tacchi MJ, Jones R, Scott J. Acute and one-year outcome of a randomised controlled trial of brief cognitive therapy for major depressive disorder in primary care. Br J Psychiatry 1997; 171:131-134.
15. Thompson LW, Coon DW, Gallagher-Thompson D, Sommer BR, Koin D. Comparison of desipramine and cognitive/behavioral therapy in the treatment of elderly outpatients with mild-to-moderate depression. Am J Geriatr Psychiatry 2001; 9:225-240.
16. Keller MB, McCullough JP, Klein DN et al. A comparison of nefazodone, the cognitive behavioral-analysis system of psychotherapy, and their combination for the treatment of chronic depression. N Engl J Med 2000; 342:1462-1470.
17. Murphy GE, Simons AD, Wetzel RD, Lustman PJ. Cognitive therapy and pharmacotherapy. singly and together in the treatment of depression. Arch Gen Psychiatry 1984; 41:33-41.
18. Scott J, Palmer S, Paykel E, Teasdale J, Hayhurst H. Use of cognitive therapy for relapse prevention in chronic depression. Cost-effectiveness study. Br J Psychiatry 2003; 182:221-227.
19. Simon J, Pilling S, Burbeck R, Goldberg D. Treatment options in moderate and severe depression: Decision analysis supporting a clinical guideline. Br J Psychiatry 2006; 189:494-501.
20. Blackburn IM, Eunson KM, Bishop S. A two-year naturalistic follow-up of depressed patients treated with cognitive therapy, pharmacotherapy and a combination of both. J Affect Disord 1986; 10:67-75.
21. Simons AD, Murphy GE, Levine JL, Wetzel RD. Cognitive therapy and pharmacotherapy for depression. Sustained improvement over one year. Arch Gen Psychiatry 1986; 43:43-48.
22. Thase ME, Rush AJ, Howland RH et al. Double-blind switch study of imipramine or sertraline treatment of antidepressantresistant chronic depression. Arch Gen Psychiatry 2002; 59:233-239.
23. Revicki DA, Wood M. Patient-assigned health state utilities for depression-related outcomes: Differences by depression severity and antidepressant medications. J Affect Disord 1998; 48:25-36.
24. Igaku Tushinsya. Quick reference to tariff for health care services Tokyo: Igaku tushinsya, 2005.
25. Yakugyou Kenkyuukai. Dictionaryfor medicines covered by health insurance. Tokyo: Jihou, 2005.
26. Cabinet Office GoJ. Estimates of GDP 2005. Tokyo: Cabinet Office, Government of Japan, 2005.
27. Ministry of Health Labour and Welfare of Japan. Patient survey. Tokyo: Ministry of Health Labour and Welfare of Japan, 2005.
28. Ministry of Internal Affairs and Communications of Japan. Labour force survey. Tokyo: Ministry of Internal Affairs and Communications of Japan, 2005.
29. Ohkusa Y, Sugawara T. Research for willingness to pay for one QALY gain. J Health Care Soc 2006; 16:157-165.
30. Kessler RC, Greenberg PE, Mickelson KD, Meneades LM, Wang PS. The effects of chronic medical conditions on work loss and work cutback. J Occup Environ Med 2001; 43:218-325.
31. Knapp M, Hidden costs of mental illness. Br J Psychiatry 2003; 183:477-478.
32. Vos T, Haby MM, Barendregt JJ, Kruijshaar M, Corry J, Andrews G. The burden of major depression avoidable by longer-term treatment strategies. Arch Gen Psychiatry 2004; 61:1097-1103.
33. Miller IW, Norman WH, Keitner GI. Cognitive-behavioral treatment of depressed inpatients: Six- and twelve-month follow-up. Am J Psychiatry 1989; 146:1274-1279.
34. Chisholm D, Sanderson K, Ayuso-Mateos JL, Saxena S. Reducing the global burden of depression: Population-level analysis of intervention cost-effectiveness in 14 world regions. Br J Psychiatry 2004; 184:393-403.
35. Jonsson B, Bebbington PE. What price depression? The cost of depression and the cost-effectiveness of pharmacological treatment. Br J Psychiatry 1994; 164:665-673.
36. Woods SW, Rizzo JA. Cost-effectiveness of antidepressant treatment reassessed. Br J Psychiatry 1997; 170:257-263.